Forest Laboratories — Proxy Contest (July 2012)
170 slides from Forest Laboratories's proxy contest presentation, Jul 20, 2012
Slide 1: Building the Future
Building the Future A Focus on Our Products & Therapeutic Categories Forest Laboratories, Inc.
Slide 2: Francis I. Perier, Jr.
Francis I. Perier, Jr. Executive Vice President, Finance & Administration and Chief Financial Officer Forest Laboratories, Inc.
Slide 3: Safe Harbor
Safe Harbor Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA ap
Slide 4: Building the Future
Building the Future A Focus on Our Products & Therapeutic Categories Forest Laboratories, Inc.
Slide 5: Howard Solomon
Howard Solomon Chairman and Chief Executive Officer Forest Laboratories, Inc.
Slide 6: Building the Future
Building the Future A Focus on Our Products & Therapeutic Categories Forest Laboratories, Inc.
Slide 7: Marco Taglietti, MD
Marco Taglietti, MD President and Chief Medical Officer, Forest Research Institute, Inc. Senior Vice President, Research & Development, Forest Laboratories, Inc.
Slide 8: Sustainable Growth Beyond 2012
Sustainable Growth Beyond 2012 Forest Laboratories, Inc.
Slide 9: Creating Sustainable Growth Beyond 2012
Creating Sustainable Growth Beyond 2012 Our “Late Eight” strategy to replace Lexapro sales nebivolol Launch, Bystolic® milnacipran Launch, Savella® ceftaroline Launch, Teflaro® roflumilast Launch, Daliresp® aclidinium Under Review linaclotide Under Review levomilnacipran NDA in 2012 Cariprazine NDA
Slide 10: Creating Sustainable Growth Beyond 2012
Creating Sustainable Growth Beyond 2012 The “Next Nine” Viibryd strategy to replace Lexapro sales nebivolol Launch, Bystolic® milnacipran Launch, Savella® ceftaroline Launch, Teflaro® roflumilast Launch, Daliresp® aclidinium Under Review linaclotide Under Review levormilnacipran NDA in 2012 caripraz
Slide 11: Strategy and Execution
Strategy and Execution Product Selection • Science-based and market-relevance • Thoughtful and thorough due-diligence Product Development • Well defined target profile and product positioning • Efficient R&D Drug development to meet target profile Post-Marketing Support • Maximize value through scie
Slide 12: R&D Facts and Figures
R&D Facts and Figures • Over 1,500 people working in R&D - 1,100+ employees and 400+ contractors - 250+ MD/PhD/PharmDs • $850MM operating budget in FY2013 • Currently, 18 Products in R&D: - 4 in Phase I/II (8 Trials) - 8 in Phase III (14 Trials) - 6 in Phase IV (8 Trials, 7 Pediatric Trials) • Manag
Slide 13: R&D Facts and Figures
R&D Facts and Figures • Global R&D Organization - 22,000+ patients, in 2,100+ sites, in 49 trials, in 21 countries in FY2012 • In the last five years: - 7 NDA/sNDA filed in 9 indications, with 6 different FDA divisions - 6 approvals... soon to be 8
Slide 14: R&D Facts and Figures
R&D Facts and Figures • Support activities in FY2012 - Toxicology – 48 Studies - Pharmacology – 40 Studies - Clinical Pharmacology – 43 Studies - Health Economics – 49 Studies - Publications – 715 Publications
Slide 15: Cardiovascular CNS Pain GI Respiratory Anti-Infectives
Cardiovascular CNS Pain GI Respiratory Anti-Infectives Bystolic nebivolol/ valsartan azimilide TTP-399 Viibryd Namenda NamendaXR cariprazine levomilnacipran Savella GRT-6005 Linaclotide Daliresp aclidinium aclidinium/ formoterol Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781
Slide 16: Cardiovascular/Metabolic
Cardiovascular/Metabolic • Maximize value of current products Bystolic Phase IV Support • 11 Phase IV Studies • +3,700 patients • Over 600 sites Life Cycle • FDC nebivolol/valsartan • Phase III ongoing • Filing in FY2014 • Expand pipeline - Azimilide (Antiarrhythmic in patients with ICD – Phase III)
Slide 17: Submission Plan
Submission Plan FY2010 FY2011 FY2012 FY2013 FY2014 FY2015 FY2016 FY2017 CY2009 CY2010 CY2011 CY2012 CY2013 CY2014 CY2015 CY2016 aclidinium NDA aclidinium/formoterol NDA azimilide NDA cariprazine NDA sNDA ceftaroline NDA Teflaro ceftaroline/avibactam NDA ceftazidime/avibactam NDA GRT6005 NDA levolmin
Slide 18: Forest R&D Summary
Forest R&D Summary • Outstanding track record in product selection, drug development and life-cycle management - A global R&D organization led by an experienced management team • Supporting the Present... - Extensive life-cycle and Phase IV programs to support currently marketed products • ...while
Slide 19: Sustainable Growth Beyond 2012
Sustainable Growth Beyond 2012 Forest Laboratories, Inc.
Slide 20: Building the Future
Building the Future A Focus on Our Products & Therapeutic Categories Forest Laboratories, Inc.
Slide 21: Gavin Corcoran, MD
Gavin Corcoran, MD Executive Vice President Research & Development, Early and Clinical Development Forest Research Institute, Inc.
Slide 22: Therapeutic categories and products
Cardiovascular Bystolic nebivolol/ valsartan azimilide TTP-399 CNS Viibryd Namenda Namenda XR cariprazine levomilnacipran Pain Savella GRT-6005 GI linaclotide Respiratory Daliresp aclidinium aclidinium/ formoterol Anti-lnfectives Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781
Slide 23: Mood Disorders Psychosis
Mood Disorders Psychosis Anxiety Depression Severe Depression Bipolar Depression Mania Schizophrenia Serotonin 5HT Norepinephrine Dopamine (SSRI & 5HT1a) Levomilnacipran (SNRI) Cariprazine (D2/D3 partial agonist)
Slide 24: Viibryd (vilazodone)
ViibrydTM (vilazadone) • SSRI with 5HT1a partial agonism • Indicated for MDD • Ongoing program to further define the utility of this drug for patients - Low dose - Relapse prevention - Pediatrics - General Anxiety Disorder
Slide 25: Levomilnacipran Pharmacology
Levomilnacipran Pharmacology • A new SNRI for the treatment of MDD - Greater selectivity for the NE transporter - More balanced increase in 5HT and NE in the brain • Relief of symptoms of depression • Potential for a positive effect on patient functionality
Slide 26: Levomilnacipran
Levomilnacipran Effect on Symptoms and Function • Three pivotal trials examining doses from 40-120mg/day - MADRS change from baseline - SDS change from baseline • Significant effect on both scores MD-01 MADRS LSMD (Placebo-Adjusted) -1 -2 -4 -5 -6 -7 * ** *** *P<0.05, **P<0.01, ***P<0.001 versus pla
Slide 27: Levomilnacipran
Levomilnacipran Effect on Symptoms and Function • Three pivotal trials examining doses from 40-120mg/day - MADRS change from baseline - SDS change from baseline • Significant effect on both scores • Dose response in study with all 3 doses (MD-01) • Lower rate of common adverse effects than most othe
Slide 28: Cariprazine Pharmacology
Cariprazine Pharmacology • Dopamine receptor partial agonist - D3 preferring, but partial agonist of D2 and D3 receptors - Less effect on histamine, adrenergic and 5HT2c • Suitable for the treatment of a range of conditions • Initial development for 2 indications - Schizophrenia and acute mania • 3
Slide 29: Significant Effect in Schizophrenia
Significant Effect in Schizophrenia Comparative Results for Schizophrenia (PANSS) Mean change from baseline RGH-MD-16 RGH-MD-04 RGH-MD-05 0 -5 Placebo -10 CAR 1.5 -15 CAR 3 -20 CAR 4.5 RIS 4 0 -5 Placebo -10 -15 CAR 3 -20 ARI 10 CAR 6 -25 -30 0 -5 Placebo -10 -15 CAR 3-6 CAR 6-9 -25 -30 0 1 2 3 4 5
Slide 30: Significant Effect in Acute Mania
Significant Effect in Acute Mania Comparative Results for Mania (YMRS) Mean change from baseline RGH-MD-31 RGH-MD-32 RGH-MD-33 0 -5 Placebo -10 CAR 3-12 -15 -20 0 -5 -10 Placebo -15 CAR 3-12 0 -5 Placebo -10 CAR 6-12 CAR 3-6 -20 0 3 6 9 12 15 18 21 0 3 6 9 12 15 18 21 0 3 6 9 12 15 18 21 Improvement
Slide 31: Favorable Adverse Event Profile
Favorable Adverse Event Profile • Most common adverse effects - Insomnia, headache, constipation • Low potential for - Clinically relevant weight gain, somnolence and EPS/EPD • Few changes on metabolic parameters - Liver enzymes, blood lipids, prolactin, CPK • Akathisia - Up to 14% in schizophrenia
Slide 32: Focus on Pain
Focus on Pain • Savella - Indicated for the treatment of fibromyalgia • GRT6005 - Novel opioid for chronic pain - Potent activity through the mu and OLR-1 receptors - Currently in Phase II • Osteoarthritis, neuropathic pain, low back pain • Cancer pain (ex-US)
Slide 33: Linaclotide
Linaclotide • Ongoing unmet need - IBS-C - Chronic constipation • Conditions characterized by - Bowel symptoms • Constipation - Abdominal symptoms • Bloating, discomfort linaclotide Lumen Cl HCO3 Na H2O GC-C CFTR P GTP cGMP PKGII Serosa Afferent pain fibers
Slide 34: Linaclotide Pivotal Data
Linaclotide Pivotal Data • Phase III - 2 large studies in CC and 2 in IBS-c - 2 long term studies • Endpoints focused on demonstrating effect on bowel and abdominal symptoms - Significant effect on all primary and secondary parameters - Relief noted within a week of therapy
Slide 35: Randomized Withdrawal
Randomized Withdrawal CC Patients Stool Frequency (CSBM) CSBMs 0 1 2 3 Treatment Period RW Period BL 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Trial Week Treatment Period 290 µg Placebo IBS-C Patients Stool Frequency (CSBM) Treatment Period RW Period CSBMs 0 1 2 3 BL 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Slide 36: Linaclotide Phase III IBS-C Trial
Linaclotide Phase III IBS-C Trial Weekly Change in Abdominal Symptoms Treatment Groups 266 µg Placebo Discomfort % Change 0 -10 -20 -30 -40 -50 -60 BL 2 4 6 8 10 12 14 16 18 20 22 24 26 Trial Week Bloating % Change 0 -10 -20 -30 -40 -50 -60 BL 2 4 6 8 10 12 14 16 18 20 22 24 26 Trial Week Fullness %
Slide 37: Robust pipeline in three therapeutic areas
Cardiovascular CNS Pain GI Respiratory Anti-Infectives Bystolic nebivolol/ valsartan azimilide TTP-399 Viibryd Namenda Namenda XR cariprazine levomilnacipran Savella GRT-6005 linaclotide Daliresp aclidinium aclidinium/ formoterol Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781 • Robust
Slide 38: Scientific programs beyond registration studies
Cardiovascular CNS Pain GI Respiratory Anti-Infectives Bystolic nebivolol/ valsartan azimilide TTP-399 Viibryd Namenda Namenda XR cariprazine levomilnacipran Savella GRT-6005 linaclotide Daliresp aclidinium aclidinium/ formoterol Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781 • Scienti
Slide 39: Therapeutic focus of complementary medicines
Cardiovascular CNS Pain GI Respiratory Anti-Infectives Bystolic nebivolol/ valsartan azimilide TTP-399 Viibryd Namenda Namenda XR cariprazine levomilnacipran Savella GRT-6005 linaclotide Daliresp aclidinium aclidinium/ formoterol Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781 • Our the
Slide 40: Building the Future
Building the Future A Focus on Our Products & Therapeutic Categories Forest Laboratories, Inc.
Slide 41: Harry J. Sacks, MD, FAAP
Harry J. Sacks, MD, FAAP Executive Director, Clinical Development – Respiratory Forest Research Institute, Inc.
Slide 42: Cardiovascular CNS Pain GI Respiratory Anti-Infectives
Cardiovascular CNS Pain GI Respiratory Anti-lnfectives Bystolic nebivolol/ valsartan azimilide TTP-399 Viibryd Namenda NamendaXR cariprazine levomilnacipran Savella GRT-6005 linaclotide Daliresp aclidinium aclidinium/ formoterol Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781
Slide 43: Improve Lives of Patients with Respiratory Diseases
Improve lives of PATIENTS WITH RESPIRATORY DISEASES Forest Laboratories, Inc.
Slide 44: Respiratory Overview
Respiratory Overview Goal: Improve lives of patients with respiratory diseases • Robust COPD development programs underway • Product differentiation studies for all products • Investigate products in other respiratory conditions such as asthma • Seek out and invest in new treatments
Slide 45: Managing the Spectrum of COPD
Managing the Spectrum of COPD Forest Laboratories, Inc.
Slide 46: Managing the Spectrum of COPD
Managing the Spectrum of COPD • Affects as many as 24 million Americans1 • Third leading cause of death in US2 • Breathlessness is leading symptom aclidinium / formoterol aclidinium Daliresp MILD MODERATE SEVERE VERY SEVERE Source: 1 COPD Foundation Website: http://www.copdfoundation.org/COPDYOU/Abo
Slide 47: Aclidinium Bromide: A Novel Anticholinergic Bronchodilator
Aclidinium Bromide: A Novel Anticholinergic Bronchodilator Efficacy Improved lung function 24 hour control Symptom relief Safety Well tolerated Low drug interaction Successful FDA AdCom Inhaler Simple to use Patient friendly
Slide 48: COPD Treatment Options
COPD TREATMENT OPTIONS Forest Laboratories, Inc.
Slide 49: Aclidinium Bromide: A Novel Anticholinergic Bronchodilator
Aclidinium Bromide: A Novel Anticholinergic Bronchodilator 350 300 250 200 150 100 -50 -100 Evening administration Aclidinium 400 ug * BID (N=29) Tiotropium 18 ug QD (N=28) Placebo (N=30) 0 1 2 4 5 6 7 8 10 11 12 13 14 16 17 18 19 20 22 23 24 Time, h Study LAS-MD-23; presented at Feb. 23, 2012 FDA A
Slide 50: Further Studies Planned
Further Studies Planned Forest Laboratories, Inc.
Slide 51: Further Studies Planned
Further Studies Planned • Relative effect of aclidinium over 24 hours - Direct comparison to approved product • Exacerbations - Confirm aclidinium reduces flare ups • Exercise Tolerance - Confirm aclidinium enables patients to better tolerate physical exertion
Slide 52: Aclidinium + Formoterol FDC
Aclidinium + Formoterol FDC Forest Laboratories, Inc.
Slide 53: Aclidinium + Formoterol FDC
Aclidinium + Formoterol FDC • Phase III pivotal studies currently enrolling • For moderate to severe patients requiring more symptom control than with a single agent - Step between monotherapy and inhaled steroids - May delay need for steroids • Established efficacy in Phase II; well tolerated • NDA
Slide 54: Importance of Reducing COPD Exacerbations
Importance of Reducing COPD Exacerbations • History of exacerbations predicts higher likelihood of future exacerbations • Reduction of exacerbations is a key component of COPD management1 • Exacerbations are associated with accelerated deterioration in lung function and increased risk of death • Dal
Slide 55: Daliresp (roflumilast)
Daliresp (roflumilast, 500 mcg tablets) Severe and Very Severe COPD “DALIRESP is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations” • Approved February 2011 - Once daily oral treatment - Fi
Slide 56: Cardiovascular CNS Pain GI Respiratory Anti-Infectives
Cardiovascular CNS Pain GI Respiratory Anti-Infectives Bystolic nebivolol/ valsartan azimilide TTP-399 Namenda NamendaXR cariprazine levomilnacipran Savella GRT-6005 linaclotide Daliresp aclidinium aclidinium/ formoterol Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781
Slide 57: Building the Future
Building the Future A Focus on Our Products & Therapeutic Categories Forest Laboratories, Inc.
Slide 58: Paul C. Grint, MD
Paul C. Grint, MD President, Cerexa, Inc.
Slide 59: Cardiovascular CNS Pain GI Respiratory Anti-Infectives
Cardiovascular CNS Pain GI Respiratory Anti-Infectives Bystolic nebivolol/ valsartan azimilide TTP-399 Namenda Namenda XR cariprazine levomilnacipran Savella GRT-6005 linaclotide Daliresp aclidinium aclidinium/ formoterol Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781
Slide 60: Bad Bugs Need Drugs
Bad Bugs Need Drugs • Antibiotic resistant infections in the US - 8 million hospital days - $20B annual cost Public health threat • National security threat • The 10 x '20 Initiative • NewDrugs4BadBugs - European initiative against antimicrobial resistance • GAIN Legislation - Generate Antibiotic In
Slide 61: Bad Bugs Need Drugs
Bad Bugs Need Drugs 10x ‘20 Ten new ANTIBIOTICS by 2020 1 ceftaroline fosamil: Forest Laboratories, Inc. Approved October 29, 2010 We could potentially deliver an additional 2 to 3 of these 10
Slide 62: Spectrum of Activity
Spectrum of Activity Resistant Gram+ Gram+ Gram– Resistant Gram– Teflaro ceftaroline + avibactam ceftazidime + avibactam MRSA MDRSP S. pneumoniae S. aureus H. influenzae E. coli K. pneumoniae ESBL producing Gram– P. aeruginosa Nabriva BC-3781
Slide 63: Ceftaroline Life Cycle Studies
Ceftaroline Life Cycle Studies patch® pediatric antibiotic therapy with ceftaroline in the hospital • Pediatric PK studies including premature newborns • Comparative studies in children - Community acquired bacterial pneumonia - Complicated skin infections - CABP at risk of MRSA • Study designs for
Slide 64: AWARE: Assessing Worldwide Antimicrobial Resistance Evaluation
AWARE: Assessing Worldwide Antimicrobial Resistance Evaluation • In Vitro US Surveillance Program • No trend of reduced susceptibility to ceftaroline for pathogens tested between 2008 and 2011 • Expanding program - 70 centers in 2011 - 200 centers in 2012 % Susceptible to ceftaroline (FDA Breakpoint
Slide 65: Important Utility of ß-Lactam Antibiotics
Important Utility of ß-Lactam Antibiotics • ß-Lactams have been effective life saving antibiotics for five decades • ß-lactamases are threatening the utility of ß-Lactams - ß-Lactamase-induced resistance is increasing worldwide - No treatment available for new extended ß-lactamases - Carbepenems are
Slide 66: Avibactam: Next Generation ß-Lactamase Inhibitor
Avibactam: Next Generation ß-Lactamase Inhibitor • Non ß-lactam ß-lactamase inhibitor - Does not bind to PBPs - No intrinsic antibacterial activity • Inhibits a broad spectrum of clinically important ß-lactamases - Older inhibitors do not offer coverage of important enzymes such as KPC or AmpC • Doe
Slide 67: Avibactam Combinations
Avibactam Combinations Globally, over a million patients a year suffer from infections known or suspected to be resistant to cephalosporins, and is expected to grow by more than 25% over the next decade • Ceftazidime Avibactam - Phase III program to treat serious Gram-negative bacterial infections h
Slide 68: BC-3781 Nabriva Therapeutics
BC-3781 Nabriva Therapeutics • Novel class of antibiotics, the pleuromutilins - Active against a wide range of Gram-positive pathogens as well as certain Gram-negative organisms • No cross resistance • Low propensity for inducing resistance itself • Developed both intravenous and oral forms to treat
Slide 69: Summary
Summary • Very significant antibiotic portfolio that covers a wide spectrum of Gram-positive and Gram-negative pathogens • Urgent medical need for new antibiotic development • Potential to deliver an additional 2 to 3 antibiotics for the IDSA 10 x ‘20 Initiative Bad Bugs Need Drugs 10x ‘20 Ten new A
Slide 70: Building the Future
Building the Future A Focus on Our Products & Therapeutic Categories Forest Laboratories, Inc.
Slide 71: David F. Solomon
David F. Solomon Senior Vice President, Corporate Development & Strategic Planning Forest Laboratories, Inc.
Slide 72: Forest Objective
Forest Objective Forest Laboratories, Inc.
Slide 73: Forest Objective
Forest Objective We will achieve long-term growth by maintaining our simple but powerful strategy License or acquire new products Rigorous scientific development Effective marketing and sales Vigorous protection of our intellectual property
Slide 74: Forest Objective
Forest Objective We will enhance long-term growth by extending that strategy Life cycle programs New therapeutic areas Earlier stage programs Larger or more difficult to manufacture molecules Adjacent business opportunities Expansion outside the United States
Slide 75: Forest Business Development
Forest Business Development Opportunistic Targeted Engineered Unsolicited Partnering Meetings Wall Street & Venture Capital Company Focus Therapeutic Franchise & Mechanism Focus Medical Meetings Companies Looking
Slide 76: Scope of Business Development Activity
Scope of Business Development Activity 350-450 Screened by Business Development 100-150 Reviewed Internally 15-25 Due Diligence 2-6 Transactions
Slide 77: Partner-Oriented Business Development: Partnerships and Acquisitions Since 2004
Partner-Oriented Business Development 25 Product Partnerships And Acquisitions Since 2004
Slide 78: Partner-Oriented Business Development
Partner-Oriented Business Development Marketed / Next 9 Product Partnerships
Slide 79: Forest is a Partner of Choice
Forest is a Partner of Choice Reputation for treating partners fairly and with respect Large enough to compete with the major pharma companies and small enough to focus on each product History of success developing and launching in-licensed products Senior level engagement across the partnership Qui
Slide 80: Continued Success of Forest's Partner-Oriented Strategy
Continued Success of Forest’s Partner-Oriented Strategy Numerous repeat collaborations with our partners Many novel and interesting product opportunities available
Slide 81: Forest is Growing its Global Footprint
Forest is Growing its Global Footprint Forest will expand where opportunities exist In 3 years, we have grown from operating in 3 countries to 10 countries Established in Canada Expanding in Europe Interest in emerging markets
Slide 82: Forest Canada
Forest Canada Forest Canada fully established Canadian rights to most of the “Next Nine” products NDS for Bystolic under review by Health Canada Launch projected early CY’13 NDS for Viibryd and linaclotide to be filed later this year, and NDS for levomilnacipran and cariprazine to be filed during CY
Slide 83: Forest Europe
Forest Europe Tosara and Forest UK (OTC Business) — Sales of ~$80M Key products are Sudacrem and Infacol Sold directly in UK and Ireland, and exported to over 35 countries
Slide 84: Forest Europe
Forest Europe Pharma Business — Sales of ~$50M Largest product is Colistin Nebulized antibiotic for prevention of respiratory infections in cystic fibrosis patients In 2011 acquired rights to Colistin in several Central EU countries Established affiliates in Germany, Austria, Netherlands, Belgium &
Slide 85: Forest Europe
Forest Europe Pharma Business — Sales of ~$50M Approval for Colobreathe in January 2012 Dry powder inhaler of the same antibiotic Will establish affiliates in all major EU countries, Scandanavia and high value Eastern EU markets Launch in Ireland, Germany, Austria, Netherlands & Denmark CY’13; addit
Slide 86: Forest Will Build Strategically in International Markets
Forest Will Build Strategically in International Markets International business must be structured to support long-term, sustainable, profitable growth Need to be sensitive to regional differences Business development to be globally deployed and looking for global and regional product rights Interna
Slide 87: Building Long-Term Growth
Building Long-Term Growth Forest has the right strategy, based on licensing and acquiring interesting products Forest will continue to build our therapeutic franchises and will be opportunistic in looking at new product and novel business opportunities Forest will expand our strategy globally
Slide 88: The Right Strategy for Today and for the Future
The Right Strategy for Today and for the Future
Slide 89: Building the Future
Building the Future A Focus on Our Products & Therapeutic Categories Forest Laboratories, Inc.
Slide 90: Elaine Hochberg
Elaine Hochberg Executive Vice President, Sales & Marketing and Chief Commercial Officer Forest Laboratories, Inc.
Slide 91: A Focus On Our Commercial Philosophy & Therapeutic Areas
A Focus On Our Commercial Philosophy & Therapeutic Areas Forest Laboratories, Inc.
Slide 92: Forest's Rich Commercial History
Forest’s Rich Commercial History Past 15 Years • Total revenue from $300MM to $4B • 14 launches - 14 products - 17 indications Significant Product Launches Celexa citalopram HBr Benicar TABLETS Lexapro Bystolic Namenda “The Forest Way” Ability to right-size and deploy commercial effort to create val
Slide 93: Commercial Operations
Commercial Operations Forest Laboratories, Inc.
Slide 94: Commercial Operations 2012
Commercial Operations 2012 ELAINE HOCHBERG Executive Vice President & Chief Commercial Officer Global Commercial & U.S. Marketing Office Based Sales Managed Markets, Government & Policy Product Management Global Commercialization Marketing Services Digital Marketing & Marketing Communications 4 Prim
Slide 95: Forest's Advantage: Field Force Strength
Forest’s Advantage: Field Force Strength RANKED 1st on Selling Power magazine’s “50 Best Companies to Sell For” in 20111 We Target per Year: • ~ 250,000 physicians • ~ 3,000 hospitals and clinics • ~ 500 senior care pharmacies Productivity2 1st Forest 2nd AstraZeneca 3rd Pfizer 4th Takeda 5th Novart
Slide 96: Primary Care
Primary Care Forest Laboratories, Inc.
Slide 97: Forest Reps Consistently Reach More Than 80% of Primary Care Physicians
Forest Reps Consistently Reach More Than 80% of Primary Care Physicians* More Than Twice Per Month Reach 90% 85% 80% 75% 70% 65% 60% Reach and Frequency to 98,000 Decile 3–10 PCP’s Reach Call Frequency 81.2% 82.5% 81.8% 83.7% 2.55 2.55 2.65 2.78 2008 2009 2010 2011 3.2 3.1 2.9 2.8 2.7 2.5 2.4 2.3 2.
Slide 98: Forest Position with PCPs is Strong and Growing Stronger
Forest Position with PCPs is Strong and Growing Stronger Company Details – Primary Care Physicians Details (thousands) 5,000 4,000 3,000 2,000 1,000 CY2007 CY2008 CY2009 Forest Merck AstraZeneca Lilly Novartis Takeda Abbott Sanofi Aventis CY2010 Pfizer GSK Boehringer CY2011 Source: IMS IPS, Office-b
Slide 99: Commercial Philosophy
Commercial Philosophy Forest Laboratories, Inc.
Slide 100: Forest's Commercial Philosophy
Forest’s Commercial Philosophy • Primarily Primary Care-Centric (with appropriate specialty overlays) • Therapeutically Agnostic • Differentiated Products • Professionally Driven • Sensibly Priced • Diversifying “Geographically”
Slide 101: Primary Care Professionals Generate >65% of TRx's
Primary Care Professionals Generate >65% of TRx’s % of TRx Decile 3-10 MDs Anti-Depressants (SRI) Beta Blockers COPD Primary Care Professionals (Includes NPs & PAs) 69% 73% 71% Specialists 23% 22% 21% Others 8% 5% 8% Total 100% 100% 100% IMS Xponent 12 months, Ending April 2012
Slide 102: Greater Than One-half of Naïve and New to Brand Patients Treated by Primary Care
Greater Than One-half of Naïve and New to Brand Patients are Treated by Primary care Physicians Percent of Patients Treated by PCPs Naïve to Market New to Brand 100% 80% 60% 40% 20% 0% 68% 64% 56% 54% 60% 60% 62% 61% HTN Depression Alzheimer COPD Source: IMS Custom Patient Study, 2012
Slide 103: Forest Competes in Major Primary Care Markets
Forest Competes in Major Primary Care Markets Ranking of Therapeutic Classes Based on Primary Care TRx Volume Total Prescriptions (000) 500,000 450,000 400,000 350,000 300,000 250,000 200,000 150,000 100,000 50,000 Cardiovascular Psychotherapeutics Antihyperlipidemic Analgesics Diabetes Anti-Infecti
Slide 104: Success with Products
SUCCESS WITH PRODUCTS Forest Laboratories, Inc.
Slide 105: Bystolic A Case Study
Bystolic A Case Study TRx (Absolute Numbers) Bystolic Prilosec Januvia Symbicort Vyvanse Bexilant Pradaxa Janumet 3,000,000 2,250,000 1,500,000 750,000 Bystolic 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Quarters Source: IMS, NPA, May 12 Note: Dexilant was originally marketed as Kapldex
Slide 106: PCP Response to Bystolic Detailing: Launches Take Two Years
PCP Response to Bystolic Detailing: Launches Take Two Years Bystolic TRx per MD 0 6 12 18 24 30 36 42 Bystolic Calls per MD Source: Internal Data, 75,970 physicians were analyzed Rx Data- IMS Xponant Year 2 Year 1
Slide 107: Strong Growth Performance in 4th Year with Broad Managed Care Coverage
Strong Growth Performance for in its’ 4th Year with Broad Coverage by Managed Care % Unrestricted T2/T3 Access Bystolic TRx 100% 80% 60% 40% 20% 0% 73% 82% 83% 84% 1,600 1,400 1,200 1,000 Total Rx (000) 1Q 08 2Q 08 3Q 08 4Q 08 1Q 09 2Q 09 3Q 09 4Q 09 1Q 10 2Q 10 3Q 10 4Q 10 1Q 11 2Q 11 3Q 11 4Q 11 1
Slide 108: Forest Pipeline
Forest Pipeline FY2013 aclidinium (COPD) linaclotide (CC/IBSc) FY2014 Namenda XR (Alzheimer’s Disease) levomilnacipran (MDD) cariprazine (schizophrenia and mania) FY15 and Beyond Bystolic / valsartan (Hypertension) aclidinium / formoterol (COPD) Viibryd (GAD) cariprazine (Depression & Bipolar Disord
Slide 109: Sales Rep High Driver of MD Adoption
Sales Rep High Driver of MD Adoption Stated and Implied Importance in Making a Prescribing Decision at Launch for Physicians DTC Advertising Sales Reps Samples Perceived Unmet Need Coverage Out-of-Pocket Cost Pre-launch Awareness Guidelines at Launch Novel MOA Expert Advocacy Dosing Manufacturer Cre
Slide 110: What Do Doctors Really Want?
What Do Doctors Really Want? “Practical” Help, Survey Finds Doctors also see a greater practical benefit in meeting with sales reps… “who are trained beyond their own product, and prepared for a serious discussion of multiple therapeutic options”. Source: “What Physicians Want” Survey by Public’s To
Slide 111: Forest's Value is in the Mix
Forest’s Value is in the Mix Industry PCP Total Prescriptions by Therapeutic Area Anti-Infectives 5% Respiratory 5% GI 5% Pain 7% CNS 11% Other 39% Cardiovascular 28% Forest Product Line Cardiovascular (3) Bystolic nebivolol/valsartan azimilide CNS (4) Viibryd Namenda/Namenda XR Cariprazine Levomiln
Slide 112: Significant Overlap Among PCPs in Different Therapeutic Areas
Significant Overlap Among PCPs in Different Therapeutic Areas SSRI 55% 3 Products 80% 2 Products 87% linaclotide COPD Beta blocker IMS Xponent 12 months, Ending April 2012
Slide 113: Forest - Diversifying Geographically
Forest - Diversifying “Geographically” Ex – US Canada Europe Latin America other US – Institutions Anti-infectives Respiratory Alzheimer’s Other
Slide 114: Average Uptake for Hospital INJ Antibiotics
Average Uptake for Hospital INJ Antibiotics: Slower Ramp and Longer Period Avg Retail Uptake Avg Hospital INJ Antibiotics Uptake Percent of Peak Volume 0% 25% 50% 75% 100% Months Post-Launch M1 M12 M23 M34 M45 M56 M67 M78 M89 M100 Source: IMS NPA Prescriptions IMS National Sales Perspectives
Slide 115: Forest's Commercial Philosophy
Forest’s Commercial Philosophy Look for efficiencies to build long term value Forest Laboratories, Inc.
Slide 116: Building the Future
Building the Future A Focus On Our Products & Therapeutic Categories Forest Laboratories, Inc.
Slide 117: William Meury
William Meury Senior Vice President, Global Commercial & US Marketing Forest Laboratories, Inc.
Slide 118: Building the Future
Building the Future A Focus on Our Products & Therapeutic Categories Forest Laboratories, Inc.
Slide 119: Cardiovascular
Cardiovascular Bystolic nebivolol/ valsartan Azimilide TTP-399 CNS Viibryd Namenda Namenda XR cariprazine levomilnacipran pain Savella GRT-6005 GI linaclotide Respiratory Daliresp aclidinium aclidinium/ formoterol Anti-Infectives Teflaro ceftaroline/avibactam ceftazidime/avibactam BC3781
Slide 120: User Trends and Prescriptions Are Strong
User Trends and Prescriptions Are Strong Cumulative Bystolic Prescribers 300,000 225,000 150,000, 75,000, 264,057 1/4/08 10/9/09 6/13/08 11/21/08 5/1/09 3/19/10 8/27/10 2/4/11 7/15/11 12/23/11 5/25/12 Over 5 Million Prescriptions Prescriptions up 20% in 1st calendar quarter vs. prior year 550 530 51
Slide 121: Market for 1st/2nd Line is Larger
Market for 1st /2nd Line is Larger Patients receiving 3 or 4 anti-hypertensives of control BP Position Bystolic Here! 26% 74% Patients received 1 or 2 anti-hypertensives to control BP Sources: Decision Resources (Pharamacor 2009); IMS/SDI (Custom) Hypertension Monthly Report, January 2012.
Slide 122: Bystolic is Being Used 1st or 2nd Line
Bystolic is Being Used 1st or 2nd Line Bystolic Line of Therapy Difference in 1st and 2nd Line 4th Line 15% 3rd Line 27% 1st & 2nd Line 58% Bystolic 4% -1% 5% 4% 3% 2% 0% (1%) (2%) Beta Blocker Market Source: IMS Study Drug Order as Written, First Filled
Slide 123: Bystolic Clinical Studies
11 Bystolic Clinical Studies Over 4 Years Study Conclusion Weiss/Greathouse Lacourciere Weiss Neutel Lacourciere Weber Saunders Punzi Registration Registration Lukic Monotherapy Monotherapy Monotherapy Stage 2 Add on to ACE, ARB, HCTZ Initial combination with ACE Black patients Hispanic patients You
Slide 124: Cardiovascular
Cardiovascular Bystolic nebivolo valsartan azimilide TTP-399 CNS Viibryd Namenda Namenda XR cariprazine levomilnacipran Pain Savella GRT-6005 GI linaclotied Respiratory Daliresp aclidinium aclidinium/formoterol Anti-Infectives Teflaro ceftaroline/ avibactam ceftazidime/avibactam BC3781
Slide 125: Bystolic + valsartan
Bystolic + valsartan 54.2MM Prescriptions ARB + BB ARB + BB + HCT ARB + HCT 10MM Rx 15.9MM Rx 28.3MM Rx $3.3B Annual Sales
Slide 126: Cardiovascular
Cardiovascular Bystolic nebivolol/valsartan azimilide TTP-399 CNS Viibryd Namenda Namenda XR cariprazine levomilnacipran Pain Savella GRT-6005 GI Linclotide Respiratory Daliresp Aclidinium Aclidinium/formoterol Anti-Infectives Teflaro Ceftaroline/avibactam Ceftazidime/avibactam BC3781
Slide 127: Namenda
Namenda Large User Base 173,000 129,750 86,500 43,250 173,000 MD Users High Satisfaction Rate 7.0 6.0 5.0 4.0 3.0 2.0 1.0 5.1 5.1 5.0 Basic ADLs Cognitive Decline Quality of Life Source: IMS XPO & Market Research
Slide 128: Once-Daily Namenda XR
Once-Daily NamendaXR (memantine HCL) extended release capsules TM
Slide 129: Once-Daily Namenda XR
Once-Daliy Namenda XR (Memantine HCI)extended release capsules Demonstrated effective with all ACHEI Improvement in cognition, function, and behavior AE consistent with Namenda Once a day high dose formulation TM
Slide 130: Viibryd is off to a Strong Start
Viibryd is off to a Strong Start Prescriptions Market Share % 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 Jul-11 Sep-11 Nov-11 Jan-12 Mar-12 TM May-12 Total Prescription Volume (000s) TRx Mkt Share Overall volume up 20% since start of 2012 Source: IMS NGPS NPA, May 2012
Slide 131: Viibryd Prescribers are on the Rise
Viibryd Prescribers are on the Rise Prescribers Since Launch Prescribers Since Launch 60,000 45,000 30,000 15,000 0 6/17/11 7/29/11 9/9/11 10/21/11 12/2/11 1/13/12 2/24/12 4/6/12 5/18/12 1,000 added/week 50,516 Source: IMS Xponent, Week ending 5/18/2012
Slide 132: Viibryd is off to a Strong Start
Viibryd is off to a Strong Start Physician Reported Use of Viibryd 4+ Line 17% 3rd Line 28% 1st Line 29% 2nd Line 26% Source: Market Research TM
Slide 133: Viibryd
Viibryd TM
Slide 134: Levomilnacipran
LEVOMILNACIPRAN Forest Laboratories, Inc.
Slide 135: Levomilnacipran
Levomilnacipran Dual Reuptake Inhibitor for Major Depressive Disorder (MDD) 200 million prescriptions written Sales for antidepressants approximately $18B Only 30–40% of patients on any achieve remission Source: STAR-D and GYK, 2008
Slide 136: Levomilnacipran
Levomilnacipran Dual Reuptake Inhibitor for Major Depression Disorder (MDD) Strong effect on the MADRAS Significant effect on function Acceptable adverse event profile Source: STAR D and GIK, 2008
Slide 137: Market Positions for Levomilnacipran
Market Positions for Levomilnacipran 1st line 2nd line 3rd line Treatment Resistant SSRIs SNRIs Wellbutrin Anti-psychotics Viibryd levomilnacipram
Slide 138: Cariprazine
CARIPARAZINE Forest Laboratories, Inc.
Slide 139: Cariprazine: A Novel Next Step
Cariprazine: A Novel Next Step D2/5HT Antagonists D2 Partial Agonist New D3/D2 Partial Agonist Risperdal Zyprexa Seroquel Geodon Clozaril Invega Saphris Fanapt Latuda Abilify Cariprazine
Slide 140: Recent Launch Performance
Recent Launch Performance Total Rx (000s) Latuda #10 Saphris #8 Fanapt #9 M1 M3 M5 M7 M9 M11 M13 M15 M17 M19 M21 M23 Source: IMS NPA TRx, March 2012
Slide 141: Bipolar Depression and MDD Markets
Bipolar Depression and MDD Markets Abilify – $5.3B 22% 26% 39% 13% Source: IMS NSP, MAT April 2012; NDTI, MAT April 2012 Note: “Others” includes Psychoses unspecified, autism, anxiety, OCD, domestic Schizophrenia Bipolar Disorder Depression Others Seroquel/XR – $5.5B 29% 17% 41% 14%
Slide 142: Cardiovascular CNS Pain GI Respiratory Anti-Infectives
Cardiovascular CNS Pain GI Respiratory Anti-Infectives Bystolic nebivolol/ valsartan azimilide TTP-399 Viibryd Namenda Namenda XR cariprazine levomilnacipran Savella GRT-6005 linaclotide Daliresp aclidinium aclidinium/ formoterol Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781
Slide 143: Current Treatments
CURRENT TREATMENTS Forest Laboratories, Inc.
Slide 144: Linaclotide Provides Multi-symptom Relief
Linaclotide Provides Multi-symptom Relief Linaclotide addresses constellation of symptoms in CC/IBSc Relieve pain Relieve bloating and discomfort Improve bowel function
Slide 145: Two Important Sources of Business
Two Important Sources of Business Convert Rx and OTC markets Prescription Market 24% $2.2B $7.0B 76% OTC Market (@ branded RX pricing) Source: Market Research & IMS
Slide 146: Linaclotide for CC and IBSc
Linaclotide for CC and IBSc (MM) CC IBS-C Total Prevalence 26.0 13.2 39.2 Patients Seeking Care 7.9 7.6 15.5 Dissatisfied Patients (62-68%) 4.9 5.2 10.1 Satisfaction with current therapies is low 60-70% of patients seeking care are dissatisfied with current therapy Lieborman Study, 2010
Slide 147: OTC Conversion Rates
OTC Conversion Rates 40% 30% 20% 10% 0% 20% NSAIDs to Cox-2s 23% H2s to PPls 37% Sedating to Non-Sedating Antihistamines Source: Kline OTC Sales Date
Slide 148: Linaclotide Post-launch
Linaclotide Post-launch Promotional Effort - +1,500 representatives - 90,000 physicians Major educational campaign directed to patients
Slide 149: Cardiovascular
Cardiovascular Bystolic Nebivolol/ Valsartan Azimilide TTP-399 CNS Viibryd Namenda Namenda XR Cariprazine Levomilnacipran Pain Savella GRT-6005 GI Linaclotide Respiratory Daliresp Aclidinium Aclidinium/ Formoterol Anti-infectives Teflaro Ceftaroline/ Avibactam Ceftazidime/ Avibactam BC3781
Slide 150: COPD Product Line
COPD Product Line Aclildinium LAMA Acilidinium /formoterol LAMA/LABA Daliresp PDEIV Inhibitor Efficacy Moderate COPD Severe COPD
Slide 151: Need for New Therapies
Need for New Therapies Patients are Still Experiencing Symptoms Despite Treatment Overall PUD PCP 70% 53% 35% 18% 0% 55% 64% 46% 41% 52% 28% Experiencing symptoms with monotherapy Experiencing symptoms with combination Spiriva + ICS/LABA Source: Forest Physician COPD Research GfK COPD Study, 2008 Pe
Slide 152: Daliresp off to a Strong Start with Pulmonologists
Daliresp off to a Strong Start with Pulmonologists Overall volume up 42% since start of 2012 7,000 6,000 5,000 4,000 3,000 2,000 1,000 PUD Share 2.6% 2.1% 1.6% 1.1% 0.6% 0.1%-0.4% PUD Market Share TRx 0 5/27/11 7/8/11 8/19/11 9/30/11 11/11/11 12/23/11 2/3/2012 3/16/12 4/27/12 Updated Weekly Data Wee
Slide 153: Daliresp off to a Strong Start
Daliresp off to a Strong Start With Pulmonologists Total PUD Users 5,000 3,750 2,500 1,250 504 1,070 1,580 1,990 2,369 2,715 3,033 3,306 3,577 3,811 4,031 Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Source: IMS Xponent, Week ending 5/25/2012
Slide 154: PCP Development
PCP DEVELOPMENT Forest Laboratories, Inc.
Slide 155: PCP Usage Doubles: 20,000 to 40,000
PCP USAGE DOUBLES: 20,000 TO 40,000 Forest Laboratories,Inc.
Slide 156: 44% Increase in Hospital Using Daliresp
44% Increase in Hospital Using Daliresp Hospitals Purchasing 1,800 1,575 1,350 1,125 1,198 +531 Hospitals 1,729 Before Hospital Launch After Hospital Launch Updated Weekly Data Week Ending May 11
Slide 157: Aclidinium
ACLIDINIUM Forest Laboratories, Inc.
Slide 158: Aclidinium
Aclidinium Long acting inhaled anti-cholinergic bronchodilator Long residence time at M3 receptors and shorter residence time at the M2 receptors Novel, multi-dose device, Genuair Rapid effect on FEV1 Low incidence of side effects Novel, easy to use inhaler
Slide 159: Aclidinium Promotional Effort
Aclidinium Promotional Effort 1,500 representatives 90,000 physicians Sampling Advertising Peer to peer promotional programs
Slide 160: Aclidinium-Formoterol
ACLIDINIUM-FORMOTEROL Forest Laboratories, Inc.
Slide 161: Cardiovascular
Cardiovascular Bystolic Nebivolol/ Valsartan Azimilide TTP-399 CNS Viibryd Namenda Namenda XR Cariprazine levomilnacipran Pain Savella GRT-6005 GI Linaclotide Respiratory Daliresp aclidinium aclidinium/ formoterol Anti-infectives Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781
Slide 162: Teflaro
Teflaro Purchasing Hospitals Above Cubicin Tygacil Zyvox TEFLARO Doribax Cubicin Vibativ Weekly Accounts Purchasing 1,500 1,125 W1 W6 W11 W16 W21 W26 W31 W36 W41 W46 W51 W56 W61 W66 W71 Weeks Post-Launch IMS, Hospital Report, 2012
Slide 163: Teflaro
Teflaro 20,000 15,000 10,000 5,000 Weekly DOT Days of Therapy Above to Zyvox W1 W6 W11 W16 W21 W26 W31 W36 W41 W46 W51 W56 W61 W66 W71 Tygacil Cubicin Doribax TEFLARO Zyvox Vibativ Weeks post-Launch Ims, Hospital Report, 2012
Slide 164: Teflaro Has Demonstrated High Efficacy Rates in CABP & ABSSSI
Teflaro Has Demonstrated High Efficacy Rates in CABP & ABSSSI Day 4 CABP TEFLARO 69.5% CABP Ceftriaxone 59.4% 0% 20% 40% 60% 80% 100% S. pneumoniae 100% 80% 60% 40% 20% 0% 85.7% 69.5% TEFLARO Ceftriaxone Day 3 ABSSSI TEFLARO 74.0% ABSSSI Vanco/Aztreonam 66.2% 0% 20% 40% 60% 80% 100% MRSA 100% 80% 60
Slide 165: Usage Patterns
Usage Patterns 40% 25% 30% 33% 20% 10% 0% Percentage of 1st line Use Emergency Department Use 100% 88% 75% 50% 25% 0% Satisfaction Source: Market Research
Slide 166: Teflaro Prescribing Intentions are High
Teflaro Prescribing Intentions are High Future Prescribing Expectation IDs and Internists 100% 2% 5% 75% 50% 98% 95% 25% 0% Plan to initiate use of Teflaro for cSSSI (n=43) Plan to initiate use of Teflaro for CABP (n=43) Source: Market Research
Slide 167: Forest Antibiotic Franchise
Forest Antibiotic Franchise First Line – Empiric Therapy Teflaro ceftaroline/avibactam ceftazidime/avibactam “Workhorse antibiotic” for cSSSI and CAP Ceftaroline with ESBL Coverage will expand use of ceftaroline for more severe infections Excellent activity against Gram- pathogens such as pseudomona
Slide 168: Gram-negative U.S. Market Share
Gram-negative U.S. Market Share Days of Therapy (non-retail) Carbapenems 14% Cephalosporins 13% IV Quinolones 34% Piperacillin/tazobactam 39% IV Quinolones Piperacillin/tazobactam Cephalosporins Carbapenems Data Source: IMS NSP Non-retail grams (MAT April 2012) converted to days of therapy using AMR
Slide 169: Cardiovascular CNS Pain GI Respiratory Anti-Infectives
Cardiovascular CNS Pain GI Respiratory Anti-Infectives Bystolic nebivolol/valsartan azimilide TTP-399 Viibryd Namenda Namenda XR cariprazine levomilnacipran Savella GRT-6005 Linaclotide Daliresp aclidinium aclidinium/formoterol Teflaro ceftaroline/avibactam ceftazidime/avibactam BC3781
Slide 170: Building the Future
Building the Future A Focus on Our Products &Therapeutic Categories Forest Laboratories, Inc.